PAM
TEVA icon

Palisade Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Palisade Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9
Closed -$182 – 628
2025
Q3 		$182 Buy
+9
New +$158 ﹤0.01% 654

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Palisade Asset Management's TEVA Position: Q4 2025 in Review

Palisade Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 9 shares — an estimated $182 sold.

Palisade Asset Management first reported a position in TEVA in Q3 2025 and held it in 1 quarter. The position peaked at $182 in Q3 2025. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Palisade Asset Management reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Palisade Asset Management sold 9 Teva Pharmaceuticals shares in Q4 2025, an estimated $182.
  • Palisade Asset Management first reported a position in Teva Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Palisade Asset Management's Teva Pharmaceuticals position peaked at $182 in Q3 2025.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Palisade Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.